Preventative effects of the albumin nano tissue-type plasminogen activator gene plasmid ultrasound microbubble carrier system on thrombosis after cardiac valve replacement

Mechanical valve replacement is a new method for treating rheumatic heart valve disease. However, patients require long-term anticoagulation therapy after surgery, thus reducing their use of anticoagulants, making the prevention of postoperative thrombosis of great research interest. We examined the potential preventative effects of the albumin nano tissue plasminogen activator (tPA) gene plasmid ultrasound microbubble carrier system on thrombosis. The average particle size of the nano tPA gene plasmid was 131.8 nm, the surface zeta potential was 30.65 +/- 40.34 mV, and the encapsulation efficiency was 76.56%, all meeting experimental requirements. One month after gene integration, the tPA content of group B had increased beyond preintegration levels and above post-integration levels of group A. After valve replacement operations, the venous blood D-Dimer ( D-D) content of group B increased significantly, whereas the venous blood D-D content of group A decreased. In addition, at 1, 2, and 4 weeks after operation, the venous blood D-D content of group B was greater than that of group A. These results suggest that the prepared albumin nano tPA gene plasmid ultrasound microbubble vector system can prevent thrombosis after heart valve replacement.